DHSC: CSA: NIHR Research Commissioning and Management Services (2027-2032)

Complete

Value

£364,000,000

Classifications

  • Research services
  • Administrative services of agencies
  • Research and development services and related consultancy services
  • General management consultancy services
  • Research consultancy services
  • Contract administration services
  • Miscellaneous business-related services
  • Business and management consultancy services
  • Social research services

Tags

  • tender

Submission Deadline

8 months ago

Published

9 months ago

Description

NIHR’s mission is to improve the health and wealth of the nation through research. Today, NIHR is the nation’s largest funder of health and care research and it invests over £1.5bn annually in domestic and international research. NIHR’s core workstreams, operating principles and areas of strategic focus are set out in the document Best Research for Best Health: The Next Chapter (2021).<br/><br/>The day-to-day operations of the NIHR are carried out by coordinating centres - the NIHR Coordinating Centre (NIHRCC) and the NIHR Research Delivery Network Coordinating Centre (RDNCC). The NIHRCC is currently made up of the following five DHSC contracts, which went live on 1st April 2018:<br/>• NIHR Evaluations, Trials and Studies Coordinating Centre (NETSCC)<br/>• Central Commissioning Facility (CCF)<br/>• NIHR Office for Clinical Research Infrastructure (NOCRI)<br/>• NIHR Academy<br/>• NIHR Centre for Engagement and Dissemination (CED)<br/><br/>These contracts will end on 31st March 2027 and through this procurement, the Authority will put in place contracts in May 2026, with Operational Services under those contracts due to commence on 1st April 2027, in order to ensure continuity of operational services for the NIHRCC.<br/>This procurement will however seek to reconfigure the services provided by the NETSCC, CCF, NOCRI and NIHR Academy contracts when they come to an end on 31st March 2027 into a new NIHRCC structure comprised of contracts procured across six Lots.<br/><br/>The Services going forward are divided into the following lots:<br/>Lot 1 – Strategic Business Services and One NIHR hub<br/>Lot 2 – Research Commissioning: Individual Level and Global Health Programmes<br/>Lot 3 – Research Commissioning: Population and Policy Level Programmes<br/>Lot 4 – Research Infrastructure Commissioning: Translational and Delivery<br/>Lot 5 – Research Infrastructure Commissioning: Applied, Public Health and Social Care<br/>Lot 6 – Research Commissioning: Career Development and Capacity Building<br/><br/>The Authority is seeking to appoint a range of suppliers to ensure that it maximises resilience across NIHR and brings to NIHR the benefits of implementing ways of working and best practice from multiple organisations. <br/><br/>Therefore, whilst there is no limitation on a single Tenderer submitting a bid for multiple Lots, the Authority is placing restrictions on the number of Lots any single Tenderer can win, and the Authority will only allow an entity to be involved in one bid submission per Lot. More information on this is set out in the procurement documents.

Similar Contracts

Open

Scientific Consultant for Medicines Discovery Catapult

Medicines Discovery Catapult (MDC) is an independent, not-for-profit innovation centre for drug discovery and part of the Catapult Network established by Innovate UK. MDC's vision is to reshape drug discovery for patient benefit by transforming great UK science into better treatments through partnership. It supports drug discovery innovators by making world-class expertise, facilities, complex technologies, and advanced analytics accessible to enable successful medicines discovery. MDC develops pioneering, impactful R&D collaborations across biotech, academia, technology companies, charities, and global pharma. It brings these communities together in active, focused national programmes that target high-risk areas of patient need. This requirement originates from the Partnership Team at Medicines Discovery Catapult (MDC), which includes national programmes across neuroscience and infection, virtual R&D, and complex medicine. The team plays a central role in enabling and accelerating UK drug discovery by identifying unmet needs, supporting ecosystem coordination, and helping to navigate the scientific and translational complexities of areas such as diseases of the brain. To fulfil its role effectively, the team must remain consistently informed about recent scientific developments, innovation opportunities, and areas of commercial promise. This enables MDC to identify and shape collaborative initiatives, support investment cases, and build strategies aligned to evolving national and global health priorities. The current emphasis has been on neuroscience, particularly neurodegenerative diseases, mental health, and drug discovery and delivery. Previous work has included: • A landscape mapping exercise to inform the strategy for the Dementia Goals Programme, providing a foundational view of the UK's capabilities, gaps, and opportunities; • Exploration of emerging scientific trends and innovation gaps within mental health, supporting the work of the Psychiatry Consortium; • Early-stage analysis on cross-cutting opportunities within complex medicine. Building on this initial work, MDC now seeks to expand the scope and focus of the landscape activity to include: • Deeper insights into priority areas aligned to the Partnership Team's strategic objectives; • A clearer understanding of challenges such as blood-brain barrier (BBB) penetration and the development of novel Central Nervous System drug modalities; • Identification of translational and commercial opportunities across neuroscience and beyond (e.g., infectious diseases). MDC requires a consultant to: • Provide ongoing scientific and strategic intelligence relevant to current and future areas of focus and interest such as neuroscience, infection, CNS drug delivery, etc. • Identify translational and commercial opportunities through horizon scanning and landscape analysis in defined scientific areas. • Support development of investment cases and programme design by synthesising internal and external data sources. • Produce materials including presentations, written briefs, dashboards, and updates for internal and external stakeholders. Deliverables would be specific for each project, but it is expected that they could include: • Monthly briefings summarising relevant scientific, policy, and/or commercial developments (oral or written). • At least one deep-dive landscape output (e.g., dashboard, short report or slide deck) per quarter, focused on agreed priority themes (e.g., BBB, emerging modalities, patient stratification). • Ad hoc input to internal programme development and stakeholder materials (e.g., funder presentations, project design). The supplier must have a proven track record of delivering high quality technical writing, with strong communication skills. A minimum of 5 years' experience in technical or scientific writing, with demonstrable experience in life sciences. Access to proprietary databases to access the relevant datasets useful for the specific projects (including OpenAlex, Europe PMC, PubMed, CrossRef, Dimensions, Lens.org (patents), ClinicalTrials.gov, WHO ICTRP, NICE Evidence). Expertise in the use of AI and language models to automate and classify data retrieval and apply thematic analyses Proven ability to synthesise scientific and commercial insights for strategic use. Previously work in areas relevant to MDC strategic mission.

Katy Reed

Published 1 hour ago

AI Bid Assistant

Our AI-powered tool to help you create winning bids is coming soon!

View Contract Source Save Contract

Timeline complete